Episode 482: Why the Framingham Heart Study Still Matters

This week on Heart Doc VIP, Dr. Joel Kahn takes a deep dive into one of the most influential research projects in cardiovascular history: the Framingham Heart Study. Launched in 1948 and still going strong, this landmark study helped identify many of the risk factors we now take for granted, including smoking, diabetes, high cholesterol, high blood pressure, obesity, and physical inactivity. Much of what modern cardiology considers "common knowledge" about prevention started in Framingham. Dr. Kahn also explores practical and emerging topics in heart health, including the role of magnesium and berberine supplementation, how to approach both low-carb and low-fat diets in a healthy way, and concerns about long-term proton pump inhibitor use. Additional discussion covers EECP therapy and strategies to improve coronary blood flow, along with the potential benefits of ezetimibe for cholesterol reduction and brain health. Thank you to this week's sponsor, Igennus. Visit igennus.com and use code DRKAHN for a special discount.

You can listen to Episode 482: Why the Framingham Heart Study Still Matters online on Radio and Podcast. Open the player on this page to stream the available audio.

Episode 482: Why the Framingham Heart Study Still Matters is an episode from Heart Doc VIP with Dr. Joel Kahn by Dr. Joel Kahn.

This episode is 24:22 long.

This episode was published on Feb 17, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Heart Doc VIP with Dr. Joel Kahn when more episodes are available from the podcast feed.